Ketamine Safety

Ketamine has a long anesthetic safety record at doses far above these, which is the reassuring part and also the part that gets over-used. The relevant question is not whether ketamine is safe in an operating room but what repeated sub-anesthetic dosing at home does over months.

Transient
Blood Pressure and Heart Rate Rise During Sessions
Dose-linked
Bladder Toxicity, Documented in Heavy Recreational Use
Thin
Long-Term Data on Repeated Therapeutic Dosing
Declined
Outcome for Patients Who Do Not Screen Safely

Cardiovascular Effects Are the Immediate Concern

Ketamine reliably raises blood pressure and heart rate for the duration of a session. In a healthy adult this is unremarkable and resolves without intervention. In someone with uncontrolled hypertension, unstable angina, a recent cardiac event, an aneurysm or significant arrhythmia it is the reason to decline treatment, and at home there is no one present to intervene if it becomes a problem. This is the single most common reason we turn patients away.

  • Transient elevation is expected and resolves as the session ends
  • Uncontrolled hypertension is a contraindication, not a caution
  • Recent cardiac events, aneurysm and significant arrhythmia rule out treatment
  • Baseline blood pressure is documented before approval, not after
  • A home setting cannot manage a hypertensive emergency, which is the point

Bladder Toxicity, Described Accurately

Ketamine-induced uropathy is real and can be severe, including irreversible bladder damage in the worst cases. It is documented overwhelmingly in heavy frequent recreational use, at doses and frequencies far beyond a supervised therapeutic course. That distinction matters, and so does not hiding behind it: the long-term data on therapeutic dosing is genuinely limited, and urinary symptoms are something we ask about at every follow-up rather than waiting to be told.

  • Severe cases are associated with heavy, frequent recreational use
  • Therapeutic-course exposure is far lower, but long-term data is limited
  • Urinary urgency, frequency, or pain are reported immediately, not at the next visit
  • New urinary symptoms pause treatment pending evaluation
  • Existing bladder or urologic conditions are assessed before starting

Dependence and Why At-Home Changes the Calculus

Ketamine has recognized misuse potential. Supervised therapeutic use at controlled intervals is a different risk profile from recreational use, but the honest complication of any at-home model is that the medication is in your house. We manage that with dispensing limits, defined intervals and counts, and we decline patients with active substance use disorders. Anyone who describes at-home ketamine as carrying no dependence risk is not being straight with you.

  • Quantities dispensed are limited, with defined intervals between sessions
  • Active substance use disorder is an exclusion, including alcohol
  • Escalating requests for earlier refills are treated as a clinical signal
  • Sessions are documented, and use outside them is not supported
  • A history of ketamine misuse specifically is a hard exclusion

The Limits of Home Monitoring

This is the section most at-home providers leave out. A clinic has staff, monitors and the ability to intervene physically. A home program has a sober support person and a phone. That is adequate for the great majority of appropriately screened patients, and it is not adequate for everyone, which is why screening is the safety mechanism rather than an administrative step.

  • A sober adult support person is required for the full session, not optional
  • Nothing is taken before the support person is physically present
  • No driving, alcohol, or safety-critical activity for the rest of the day
  • Patients who cannot arrange a support person cannot be treated here
  • Presentations needing continuous monitoring are referred to a clinic

Interactions, Checked Individually

Interaction risk is handled drug by drug rather than by category, which is why the directory exists as a separate corpus on this site. Some combinations change dosing, some change timing, and a few rule out treatment entirely.

  • Benzodiazepines may blunt response and are discussed before starting
  • Opioids share respiratory-depressant effects and need careful review
  • Stimulants are held on session days for additive cardiovascular reasons
  • MAOIs require specific evaluation before any decision
  • Alcohol is not a grey area on session days; it is excluded

Who We Decline

Stating exclusions plainly is more useful than listing them in small print after a payment page. These are not negotiable and are assessed before money changes hands.

  • Uncontrolled hypertension or significant cardiovascular disease
  • Active psychosis, schizophrenia, or untreated bipolar mania
  • Active substance use disorder, including alcohol use disorder
  • Pregnancy or breastfeeding
  • Active suicidal planning, which needs a higher level of care than telehealth
  • No sober support person available for sessions

The Safety Literature

A systematic review of side effects associated with ketamine use in depression, covering cardiovascular, psychiatric, cognitive and urologic effects across the treatment literature. Notes directly that data on repeated and long-term dosing remains limited, which is the caveat this page is built around. (Short et al., 2018 (Lancet Psychiatry))

The American Psychiatric Association consensus statement on ketamine in mood disorders, setting out patient selection, cardiovascular screening, monitoring and follow-up standards. These are the standards this practice applies and the basis for the exclusions listed above. (Sanacora et al., 2017 (JAMA Psychiatry))

The reference efficacy trial in treatment-resistant depression, which also documented the transient dissociative and cardiovascular effects that define the monitoring requirements for this treatment. (Zarate et al., 2006 (Archives of General Psychiatry))

Frequently Asked Questions

Is at-home ketamine as safe as a clinic?

For appropriately screened patients the safety difference is small, and screening is what makes that sentence true rather than the setting itself. A clinic can intervene physically and monitor continuously; a home cannot. That is precisely why the exclusion criteria here are strict and why some patients are referred to an infusion clinic instead. Any at-home provider claiming equivalence for all patients is not screening properly.

Will this damage my bladder?

The severe cases in the literature involve heavy frequent recreational use, at exposures well beyond a supervised course. The honest position is that long-term data on therapeutic dosing is limited, so we ask about urinary symptoms at every follow-up rather than assuming absence. Report urgency, frequency, or pain immediately; new urinary symptoms pause treatment pending evaluation.

Can I get addicted?

There is recognized misuse potential, and having the medication at home is a genuine complication that clinic models do not have. It is managed with limited quantities, defined intervals, documented sessions, and declining patients with active substance use disorders. If you notice yourself wanting to use it outside sessions, that is something to raise rather than manage privately.

Do I really need someone with me?

Yes, and it is not waivable. You will be impaired for a period, judgment and coordination included, and the presence of a sober adult is the main safety mechanism a home setting has. If you cannot arrange one, you cannot be treated here. Providers who let patients dose alone have removed the only monitoring the model had.

What if I have high blood pressure?

Controlled and stable on medication is usually workable. Uncontrolled is a contraindication, because ketamine raises blood pressure further and a home setting has no way to manage a hypertensive emergency. We document a baseline before approving treatment. If yours is not controlled, treating that first is the necessary step, and we will say so.

Dr. Ben Soffer, D.O., Medical Director, Tovani Health
Medically reviewed

Dr. Ben Soffer, D.O.

Medical Director, Tovani Health

Board-certified in Internal Medicine (ABIM) · Licensed in Florida, New Jersey & California

Dr. Soffer is a board-certified physician and the founder and sole prescribing clinician at Tovani Health. He personally reviews every patient’s eligibility and oversees at-home ketamine treatment for depression, anxiety, PTSD, and chronic pain.

Last reviewed August 2026 · About the physician

Interactive: Scroll-through explainer

See ketamine's mechanism, animated

A 60-second visual walk-through from NMDA receptor blockade to new synaptic connections, with every claim cited to PubMed.

Explore the science

Go deeper: clinical guides

Plain-English, evidence-based guides: what the condition is, what helps, and where ketamine fits. Educational, not a diagnosis.

Ready to Start Healing?

Check your eligibility in under 5 minutes. Free, no obligation.